Table 2.
Illness presentation
| Postinpatient | Community | |
| Median (IQR) duration of symptoms prior to contact with VH | 7 (4, 11.5) n=188 | 7 (5, 14) n=307 |
| Length of stay prior to admission to VH (postinpatient group) | ||
| Median (IQR) | 4 (3, 8) | |
| 3 days or less—N (%) | 159/415 (38.3%) | |
| 4–5 days—N (%) | 91/415 (21.9%) | |
| 6+ days | 165/415 (39.8%) | |
| ITU admission during hospital stay prior to VH (postinpatient group) | 11 (2.5%) | |
| Shortness of breath | 295/438 (67.4%) | 319/449 (71.1%) |
| Cough | 301/438 (68.7%) | 341/450 (75.8%) |
| Fever | 284/438 (64.8%) | 281/449 (62.6%) |
| Chest pain | 57/438 (13.0%) | 118/449 (26.3%) |
| Diarrhoea | 72/438 (16.4%) | 61/449 (13.6%) |
| Headache | 46/438 (10.5%) | 82/449 (18.3%) |
| Myalgia | 88/438 (20.1%) | 129/449 (28.7%) |
| Fatigue | 128/438 (29.2%) | 137/449 (30.4%) |
| COVID test result | ||
| Positive | 271/445 (60.9%) | 143/455 (31.4%) |
| Negative | 156/445 (35.1%) | 193/455 (42.4%) |
| Not done | 9/445 (2.0%) | 95/455 (20.9%) |
| Not valid/Pending | 9/445 (2.0%) | 24/455 (5.3%) |
| Abnormal CXR | 303 (77.5%) | 208 (48.9%) |
| Oxygen saturation | ||
| ≤91 | 36/309 (11.7%) | 5/377 (1.3%) |
| 92–93 | 31/309 (10.0%) | 13/377 (3.5%) |
| 94–95 | 61/309 (19.7%) | 33/377 (8.8%) |
| ≥96 | 181/309 (58.6%) | 326/377 (86.5%) |
| Baseline blood tests median values and categories | ||
| Platelets | 268.5 (189.5, 364) | 241 (188, 300) |
| <150 | 37 (9.6%) | 41 (11.0%) |
| 150–450 | 300 (78.1%) | 324 (86.9%) |
| >450 | 47 (12.2%) | 8 (2.1%) |
| WCC | 6.85 (5.35, 9) | 6.8 (5.3, 8.9) |
| <4 | 30 (7.8%) | 26 (7.0%) |
| 4–11 | 307 (80.0%) | 300 (80.4%) |
| 11 | 47 (12.2%) | 47 (12.6%) |
| Lymphocytes | 1.15 (0.8, 1.62) | 1.47 (1.03, 2.12) |
| <0.8 | 95 (24.7%) | 53 (14.2%) |
| 0.8–5.0 | 288 (75.0%) | 319 (85.5%) |
| >5.0 | 1 (0.3%) | 1 (0.3%) |
| Eosinophils | 0.06 (0.01, 0.14) | 0.06 (0.01, 0.18) |
| <0.5 | 374 (97.4%) | 354 (94.9%) |
| 0.5–1.0 | 8 (2.1%) | 16 (4.3%) |
| >1.0 | 2 (0.5%) | 3 (0.8%) |
| CRP | 43.75 (16.4, 74)1 | 8.25 (0.00, 42.35) |
| Normal | 44 (12.0%) | 157 (43.6%) |
| 5–19 | 58 (15.8%) | 67 (18.6%) |
| 20–100 | 205 (55.7%) | 108 (30.0%) |
| >100 | 61 (16.6%) | 28 (7.8%) |
| eGFR (CKD stage) | 89.8 (71.2, 108.0) | 88.8 (77.2, 98.9) |
| ≥90 (normal) | 188 (49.5%) | 170 (46.0%) |
| 60–89 (stage 2) | 139 (36.6%) | 174 (47.0%) |
| 45–59 (stage 3a) | 28 (7.4%) | 21 (5.7%) |
| 30–44 (stage 3b) | 19 (5.0%) | 2 (0.5%) |
| 15–29 (stage 4) | 5 (1.3%) | 3 (0.8%) |
| <15 (stage 5) | 1 (0.3%) | 0 (0.0%) |
| Risk status | ||
| High risk | 388 (88.8%) | 408 (89.9%) |
| Low risk | 49 (11.2%) | 46 (10.1%) |
CKD, chronic kidney disease; CRP, C reactive protein; CXR, chest X-ray; eGFR, estimated glomerular filtration rate; ITU, intensive therapy unit; VH, virtual hospital; WCC, white cell count.